Skip to main content
    L

    LENZ Therapeutics Inc (LENZ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.57
    +0.14 (+4.08%)

    Market Cap: $107.77M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    33%(7/21)
    Avg Surprise
    -628.25%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.98
    Range$-1.07 - $-0.85
    6 analysts
    EPS Revisions
    3
    0
    7d
    4
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.02+4.1%
    60d ago$-0.94-3.7%
    30d ago$-0.980.0%
    7d ago$-0.980.0%
    Current$-0.98
    Revenue Consensus
    $4M
    Range$2M - $9M
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.12
    Range$-1.43 - $-0.71
    6 analysts
    Revenue Consensus
    $8M
    Range$5M - $12M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.12---
    Sep 26EST
    		-$-0.98---
    Jun 26
    Reported Aug 11
    		$-1.02$-1.21+15.70%Beat-92.5%
    Mar 26
    Reported May 11
    		$-1.32$-1.07-23.31%Miss-149.1%
    Dec 25
    Reported Mar 24
    		$-1.16$-0.92-26.09%Miss-152.2%
    Sep 25
    Reported Nov 5
    		$-0.59$-0.67+11.94%Beat-55.3%
    Jun 25
    Reported Jul 30
    		$-0.53$-0.54+1.85%Beat-32.5%
    Mar 25
    Reported May 7
    		$-0.53$-0.32-65.63%Miss+85.0%
    Dec 24
    Reported Mar 19
    		$-0.46$-0.42-9.52%Miss-15.0%
    Sep 24
    Reported Nov 6
    		$-0.38$-0.43+11.63%Beat-58.3%
    Jun 24
    Reported Aug 14
    		$-0.40$-0.67+40.30%Beat+94.1%
    Mar 24
    Reported May 8
    		$-3.53$-0.82-330.49%Miss-17.3%
    Dec 23
    Reported Feb 27
    		$-0.40$-0.13-207.69%Miss+87.0%
    Sep 23
    Reported Nov 13
    		$-0.24$-0.24+0.00%Beat+92.4%
    Jun 23
    Reported Sep 11
    		$-6.79$-0.97-600.00%Miss-102.1%
    Mar 23
    Reported Jun 28
    		$-3.01$-0.40-660.68%Miss+10.4%
    Dec 22
    Reported Mar 29
    		$-3.08$-0.49-524.11%Miss-25.7%
    Sep 22
    Reported Dec 29
    		$-3.15$-0.44-608.98%Miss-5150.0%
    Jun 22
    Reported Sep 28
    		$-3.36$-0.49-583.90%Miss+86.1%
    Mar 22
    Reported Jun 28
    		$-3.36$-0.39-761.54%Miss-888.2%
    Dec 21
    Reported Mar 29
    		$-2.45$-0.30-723.53%Miss-
    Sep 21
    Reported Dec 29
    		$-0.06N/A+78.32%Beat-
    Jun 21
    Reported Sep 28
    		$-24.15$-0.29-8227.59%Miss-
    Mar 21
    Reported Jun 28
    		$-0.34$0.00N/AMiss-

    Dividends

    Dividend Metrics

    Forward Yield0.00%
    Forward Annual Dividend$0.00

    Key Metrics

    Valuation
    P/E Ratio-0.87EV/EBITDAN/A
    Price/FCF-0.98xFCF Yield-102.15%
    Profitability
    Profit Margin0.00%Operating Margin-623.00%
    ROE-59.20%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio13.55xQuick Ratio13.31x
    Trading Statistics
    Beta1.73Avg Volume775.56K
    52-Week High$39.9452-Week Low$3.35

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.58
    SMA 20$3.74
    SMA 50$4.45
    SMA 200$8.74
    EMA 10$3.60
    EMA 20$3.81
    EMA 50$4.41
    EMA 200$9.80

    MACD

    Line: -0.29Signal: -0.31Hist: 0.02

    ADX

    ADX: 26.0+DI: 16.7-DI: 32.3

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down96.0
    PSAR$3.78

    Bollinger Bands

    Upper Band$4.17
    Lower Band$3.32
    %B Position2271%(Upper)
    Band Width0.29

    RSI (14-Day)

    Neutral
    38.3

    Momentum Oscillators

    Stoch %K18.4
    Stoch %D20.6
    Williams %R-65.4
    ROC (10d)-5.8%
    Momentum-0.22
    CCI (20d)-76.0
    MFI (14d)32.2

    Volatility Measures

    ATR (14d)$0.24(6.8%)
    StdDev (20d)0.21
    Hist Vol59.2%(High)

    Volume Flow

    VWAP$3.55
    OBV-42.9M
    AD Line-36.0M
    CMF (20d)0.015

    Volume Metrics

    Avg Vol (20d)770.5K
    Vol Ratio1.0x
    VWMA (20d)$3.73

    Pivot Points

    R3$3.85
    R2$3.73
    R1$3.58
    Pivot Point$3.46
    S1$3.31
    S2$3.19
    S3$3.04

    Advanced Oscillators

    TSI-31.35
    Ultimate Osc45.2
    KST-206.71

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$5.49M$1.90M$1.59M$12.50M$5.00M$0$66,000$0$0$0$0$0
    Cost of Revenue$280,000$1.08M$418,000$0$0$0$33,000$0$0$0$142,000$0
    Gross Profit$5.21M$825,000$1.17M$12.50M$5.00M$0$33,000$0$0$0$-142,000$0
    Operating Expenses$39.38M$44.96M$39.63M$31.39M$21.86M$16.93M$15.22M$12.95M$14.35M$16.09M$24.99M$19.86M
    R&D$0$0$0$3.79M$9.06M$5.82M$5.87M$6.45M$6.95M$10.54M$19.54M$17.00M
    SG&A$39.38M$44.96M$39.63M$27.60M$12.80M$11.11M$9.36M$6.49M$7.41M$5.55M$5.45M$2.86M
    Operating Income$-34,172,000$-44,135,000$-38,463,000$-18,887,000$-16,857,000$-16,931,000$-15,225,000$-12,945,000$-14,352,000$-16,088,000$-24,989,000$-19,865,000
    Interest Income$2.27M$2.64M$2.99M$2.20M$2.25M$2.32M$2.57M$2.74M$2.46M$788,000$852,000$1.09M
    Interest Expense$0$0$0$0$0$0$0$0$0$560,000$0$0
    Income Before Tax$-31,915,000$-41,488,000$-35,894,000$-16,700,000$-14,412,000$-14,619,000$-12,651,000$-10,215,000$-10,254,000$-16,648,000$-23,871,000$-18,880,000
    Income Tax Expense$3,000$0$0$0$500,000$0$0$0$0$0$0$0
    Net Income$-31,918,000$-41,488,000$-35,896,000$-16,700,000$-14,912,000$-14,619,000$-12,652,000$-10,215,000$-10,254,000$-16,648,000$-23,692,000$-18,880,000
    EBITDA$-34,206,000$-44,337,000$-39,381,000$-19,555,000$-17,527,000$-18,040,000$-16,616,000$-14,300,000$-13,658,000$-17,706,000$-25,230,000$-20,489,000
    EBIT$-34,185,000$-44,132,000$-38,880,000$-18,901,000$-16,658,000$-16,942,000$-15,217,000$-12,951,000$-12,717,000$-17,436,000$-24,723,000$-19,966,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about LENZ

    News

    Insiders Re-Evaluate Their US$654.9k Stock Purchase As LENZ Therapeutics Falls To US$113m

    Insiders at LENZ Therapeutics, Inc. (NASDAQ:LENZ) who purchased US$654.9k worth of stock at an average price of US$12.15 are now seeing their investment fall to US$183.2k due to a 10% price decline...

    Simply Wall Street•10/14/26•Somewhat-Bearish

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

    Pomerantz LLP is investigating LENZ Therapeutics, Inc. (NASDAQ: LENZ) on behalf of investors for potential securities fraud. This investigation follows a sharp drop in Lenz's stock price after Bank of America downgraded...

    FinancialContent•10/6/26•Bearish

    Investigation launched into LENZ Therapeutics over possible securities fraud after weak sales report.

    Pomerantz LLP has initiated an investigation into LENZ Therapeutics following its weaker-than-expected Q2 2026 results...

    Pluang•10/1/26•Bearish

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

    Pomerantz LLP is investigating LENZ Therapeutics, Inc. (NASDAQ: LENZ) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows Lenz's August 11, 2026...

    FinancialContent•9/22/26•Bearish

    LENZ Therapeutics, Inc. (LENZ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

    Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against LENZ Therapeutics, Inc. (LENZ) following a significant drop in its stock price. This decline occurred after the company reported disappointing...

    ACCESS Newswire•9/11/26•Neutral

    LENZ Valuation and Fair Value

    P/E
    -0.9x
    P/FCF
    -1.0x
    P/B
    0.5x
    See GNG's fair value

    LENZ Profitability: Margins, ROIC and FCF

    Gross margin
    91.7%
    Operating margin
    -623.0%
    Net margin
    0.0%
    ROE
    -59.2%
    FCF margin
    -532.8%
    FCF yield
    -102.2%

    LENZ Competitors

    CompanyTicker
    Tonix Pharmaceuticals Holding CorpTNXP
    enGene Holdings Inc. Common StockENGN
    Foghorn Therapeutics IncFHTX
    Stereotaxis IncSTXS
    Cellectis SACLLS
    Genelux Corporation Common StockGNLX
    vTv Therapeutics IncVTVT
    Definitive Healthcare CorpDH

    Sector: Healthcare

    LENZ Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    0
    Buy
    5
    Hold
    2
    Sell
    0
    Strong Sell
    0

    LENZ Bull Case vs Bear Case

    Bull case

    • 71.4% of LENZ's analyst ratings are Buy or Strong Buy.

    LENZ Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -10.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.98
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    4 up, 3 down

    LENZ Dividend

    Forward yield
    0.0%

    Frequently Asked Questions About LENZ

    Does LENZ pay dividends?

    LENZ Therapeutics Inc (LENZ) has a dividend payment track record. See the LENZ dividend history page for its current payment status, TTM yield, and recorded payments.

    What is LENZ's market cap?

    LENZ Therapeutics Inc (LENZ) has a market capitalization of $107.77M with a current stock price of $3.57.

    Related stocks

    Sector: Healthcare

    All stocks starting with L

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In